Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Hairy and enhancer of split homolog-1 (HES-1) mediates the proliferative effect of Beta-estradiol on breast cancer cell lines

Authors: A Ström, N Arai, J Leers, J-Å Gustafsson

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

The mechanism behind estradiol-dependent growth of breast cancer is presently not well understood. We show that the hairy and enhancer of split homolog-1 (HES-1) protein level in the breast cancer cell lines T47D and MCF-7 is down-regulated by 17β-estradiol treatment. This regulation could be reversed by addition of the anti-estrogens 4OH tamoxifen, raloxifen and Imperial Chemical Industries (ICI) 182,780. Furthermore, T47D cells with inducible exogenous HES-1 expression showed that HES-1 protein needs to be removed in order for 17β-estradiol to have a proliferative effect and subsequently up-regulating proliferating cell nuclear antigen (PCNA). …
Metadata
Title
Hairy and enhancer of split homolog-1 (HES-1) mediates the proliferative effect of Beta-estradiol on breast cancer cell lines
Authors
A Ström
N Arai
J Leers
J-Å Gustafsson
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr152

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Meeting abstract

Development of a high throughput, molecular diagnostic assay for predicting telomerase activity in breast cancer cell lines and tissues

Oral presentation

Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results

Oral presentation

Genetic testing for BRCA1 and BRCA2 mutations - ready for implementation?

Meeting abstract

Relation of gene expression-based tumor subclasses to clinical phenotypes

Meeting abstract

Genetic variants of CYP19 (aromatase) and breast cancer risk

Meeting abstract

One test to identify 50% of all Norwegian BRCA1 mutations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits